← Browse by Condition
Medical Condition

diabetic macular edema

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for diabetic macular edema sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — diabetic macular edema Clinical Trials

How many clinical trials are currently recruiting for diabetic macular edema?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for diabetic macular edema, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for diabetic macular edema?
diabetic macular edema research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a diabetic macular edema clinical trial?
Eligibility criteria for diabetic macular edema trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Phase 3
1
Top Sponsors
Vastra Gotaland Region 2 trials
Alvotech Swiss AG 1 trial
Frontera Therapeutics 1 trial
Abdulkadir Küçük 1 trial
Sierra Eye Associates 1 trial

Recruiting Clinical Trials

NCT07489131 Phase 3
Recruiting
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
Enrollment
256 pts
Location
Hungary
Sponsor
Alvotech Swiss AG
View Trial →
NCT06549023
Recruiting
Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy
Enrollment
40 pts
Location
Sweden
Sponsor
Vastra Gotaland Region
View Trial →
NCT05916391 Phase 1
Recruiting
Gene Therapy for Diabetic Macular Edema
Enrollment
18 pts
Location
China
Sponsor
Frontera Therapeutics
View Trial →
NCT07821450
Recruiting
Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study
Enrollment
60 pts
Location
Turkey (Türkiye)
Sponsor
Abdulkadir Küçük
View Trial →
NCT06984822
Recruiting
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
Enrollment
150 pts
Location
Sweden
Sponsor
Vastra Gotaland Region
View Trial →
NCT06942520 Phase 2
Recruiting
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Enrollment
18 pts
Location
United States
Sponsor
Sierra Eye Associates
View Trial →

Related Conditions

proliferative diabetic retinopathy (1) diabetic retinopathy (1) diabetic retinopathy visually threatening (1) diabetes mellitus type 1 (1) diabetes mellitus type 2 (1) blepharoptosis (1) age related macular degeneration (1) visual impairment (1) diabetes mellitus (1) hyperglycaemia diabetic (1) oxidative stress (1) vascular endothelial growth factor (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology